tailieunhanh - báo cáo khoa học: "Novel therapies in breast cancer: what is new from ASCO 2008"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Novel therapies in breast cancer: what is new from ASCO 2008 | BioMed Central Journal of Hematology Oncology Review Open Access Novel therapies in breast cancer what is new from ASCO 2008 David Chu and Janice Lu Address Division of Medical Oncology Department of Medicine State University of New York at Stony Brook Stony Brook New York USA Email David Chu - Janice Lu - Corresponding author Published I October 2008 Received 31 July 2008 Journal of Hematology Oncology 2008 1 16 doi 1756-8722-1-16 Accepted 1 October 2008 This article is available from http content 1 1 16 2008 Chu and Lu licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Breast cancer is the most common female cancer and the second most common cause of female cancer-related deaths in the United States. World-wide more than one million women will be diagnosed with breast cancer annually. In 2007 more than 175 000 women were diagnosed with breast cancer in the United States. However deaths due to breast cancer have decreased in the recent years in part because of improved screening techniques surgical interventions understanding of the pathogenesis of the disease and utilization of traditional chemotherapies in a more efficacious manner. One of the more exciting areas of improvement in the treatment of breast cancer is the entrance of novel therapies now available to oncologists. In the field of cancer therapeutics the area of targeted and biologic therapies has been progressing at a rapid rate particularly in the treatment of breast cancer. Since the advent of imatinib for the successful treatment of chronic myelogenous leukemia in the 2001 clinicians have been searching for comparable therapies that could be as efficacious and as